Zepatier
(Grazoprevir)PreclinicalSmall molecule
Merck & Co.Grazoprevir is used to treat hepatitis C, a viral infection that damages the liver. It works by stopping the hepatitis C virus from reproducing in the body.[1] Zepatier is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Zepatier is one of 82 small molecule programs targeting Hepatitis C Virus Infection. It is currently in Preclinical.
3
Indications
26
Total Trials
0
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Viral Disease
#DrugCompanyPhaseTrials
1Tivicay
GSKApproved
Cabenuva
GSKApproved
Tyzeka
NovartisApproved
Hepsera
GileadApproved
Vemlidy
GileadApproved
Viread
GileadApproved
Vistide
GileadApproved
Incivek
Vertex PharmaceuticalsApproved
Ziagen
GSKApproved
Sunlenca
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis17 trials
Show 14 more trials
Hepatitis C5 trials
Show 2 more trials
Hepatic Insufficiency1 trial
Renal insufficiency1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Grazoprevir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company